Lucentis Alternatives Compared
| Lucentis | Byooviz | Eylea |
|
|---|
| Lucentis (ranibizumab) | Byooviz (ranibizumab) | Eylea (aflibercept) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Degeneration, Diabetic Macular Edema, Myopic Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema. Lucentis may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Macular Degeneration, Myopic Choroidal Neovascularization, Macular Edema. Byooviz may also be used for purposes not listed in this medication guide. |
Prescription only
Eylea is a VEGF (vascular endothelial growth factor) inhibitor that is used to treat a variety of eye conditions that may affect your vision, such as macular degeneration, diabetic retinopathy (DR)... View more |
Related suggestions Macular Degeneration
Macular Edema
Popular comparisons
|
|||||||||||||||||||||||
| More about Lucentis (ranibizumab) | More about Byooviz (ranibizumab) | More about Eylea (aflibercept) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Lucentis has an average rating of 7.0 out of 10 from a total of 13 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
Be the first to share your experience with this drug. |
Eylea has an average rating of 6.5 out of 10 from a total of 41 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Common side effects include:
See also: Lucentis side effects in more detail. |
See also: Byooviz side effects in more detail. |
See also: Eylea side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Lucentis prices |
View all Byooviz prices |
View all Eylea prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | Other ranibizumab brands include: Cimerli, Lucentis, Susvimo |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
216 hours |
216 hours |
144 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 1 drugs are known to interact with Lucentis:
|
A total of 1 drugs are known to interact with Byooviz:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.